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ABSTRACT 
Protein Kinase A (PKA) is a well known member of the serine-threonin protein kinase super-
family. PKA, also known as cAMP-dependent protein kinase, is a multi-unit protein kinase 
that mediates signal transduction of G-protein coupled receptors through its activation upon 
cAMP binding. The widespread expression of PKA subunit genes, and the myriad of mecha-
nisms by which cAMP is regulated within a cell suggest that PKA signaling is one of extreme 
importance to cellular function. It is involved in the control of a wide variety of cellular pro-
cesses from metabolism to ion channel activation, cell growth and differentiation, gene ex-
pression and apoptosis. Importantly, since it has been implicated in the initiation and progres-
sion of many tumors, PKA has been proposed as a novel biomarker for cancer detection,  and 
as a potential molecular target for cancer therapy. Here, we highlight some features of cAMP/ 
PKA signaling that are relevant to cancer biology and present an update on targeting PKA in 
cancer therapy. 
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THE cAMP-DEPENDENT SIGNALING 
PATHWAY AND ITS EFFECTORS:  
AN OVERVIEW 
Adenosine 3’5’-cyclic monophosphate 
(cyclic AMP, cAMP) was first identified as a 
small intracellular heat-stable factor mediat-
ing the effect of glucagon on the phosphory-
lation status of glycogen phosphorylase in 
the 1950s, and the concept of cAMP as an 
important mediator for many extracellular 
signaling molecules was rapidly developed 
(Beavo and Brunton, 2002). 
cAMP is present in every cell, where it is 
generated from ATP by adenylate cyclases, 
ACs, and can be induced more than twenty-
fold upon activation of ACs by extracellular 
signals (Hanoune and Defer, 2001). Degra-
dation of cAMP is mediated by cAMP phos-
phodiesterases, PDEs, that hydrolyze cAMP 
into adenosine 5’-monophosphate and this 
event is important for controlling cAMP rest-
ing state levels (Omori and Kotera, 2007).  
So, intracellular concentration of cAMP 
results from the fine balance between the ac-
tivities of synthesis and degradation by ade-
nylate cyclases and cAMP phosphodiesteras-
es, respectively.  
A large number of hormones, neuro-
transmitters and other signal substances uti-
lize cAMP as an intracellular second mes-
senger, so that the rate of cAMP production 
and degradation is sensitive to a wide range 
of extracellular and intracellular signals, and 
cAMP can directly regulate a variety of cell 
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functions (Gancedo, 2013). Within each cell, 
cAMP may activate different proteins. For 
example cAMP may operate directly on ion 
channels (Biel, 2009). 
An important additional effector system 
for cAMP signaling is achieved by the ex-
change proteins directly activated by cAMP 
1 and 2, Epac1 and Epac2, also named 
cAMP-GEFI and -II. These guanine nucleo-
tide exchange factors (GEFs) are specific 
activators of the small GTPase Rap1 
(Schmidt et al., 2013). The cAMP-binding 
domain of Epac can bind one molecule of 
cAMP, resulting in a conformational change 
of the protein, which will expose the active 
site of the catalytic domain, enabling the pro-
tein to bind to and activate Rap1 (De Rooij 
et al., 1998).  
However, the main intracellular target for 
cAMP in mammalian cells is the cAMP-
dependent protein kinase (PKA; EC 
2.7.1.37) we will discuss on extensively be-
low (Taskén et al., 1997).  
cAMP, either via a PKA-dependent or 
PKA-independent manner, affects numerous 
cellular functions such as metabolism, ion 
channel activation, cell growth and differen-
tiation, gene expression and apoptosis (An-
toni, 2012).  
On the other hand, the cAMP pathway 
interacts with other intracellular signaling 
pathways, including cytokine and Ras-Raf-
Erk pathways (Yu et al., 2013; Kostenko et 
al., 2011; Spina et al., 2013; Follin-Arbelet 
et al., 2013; Tai et al., 2014). 
Notably, these signaling connections play 
an important role in cancer biology and a 
combined blockade of such signaling path-
ways is considered a relevant strategy for 
therapeutic intervention (Awada and Afti-
mos, 2013; Colzani et al., 2014). 
The existence of different cAMP down-
stream effectors and some features of PKA 
signaling pathway may contribute to explain 
how differential discrete effects of cAMP 
may be obtained (Skalhegg and Tasken, 
2000). 
An important concept is that cAMP con-
centration and cAMP signaling can change 
and occur very locally, respectively (Ed-
wards et al., 2012; Lefkimmiatis and Zacco-
lo, 2014). 
Localized cAMP-mediated activity is ex-
plained by localized induction and degrada-
tion of cAMP by PDEs in specialized cellu-
lar compartments such as caveolae and lipid 
rafts (Simons and Ikonen, 1997). Also ACs 
and GPCRs are not evenly distributed along 
the membrane (Willoughby and Cooper, 
2007; Steinberg and Brunton, 2001).  
Noteworthy, in the same cell, elevation 
of cAMP and subsequent PKA activity by 
different agonists can lead to different physi-
ological responses, even because receptors 
for extracellular signaling molecules can ac-
tivate only a fraction of PKA that are largely 
segregated in subcellular microdomains by a 
great number of PKA Anchoring Proteins, 
AKAPs (Beene and Scott, 2007). AKAPs are 
bound to cytoskeletal proteins or organelles 
and bind regulatory subunits of the PKA, so 
that the PKA can be docked and concentrat-
ed close to crucial targets and, despite their 
broad substrate specificity, can phosphory-
late only selected proteins (Gold et al., 
2006). 
This all contributes to a localized activa-
tion of PKA. 
 
PKA: GENERAL FEATURES,  
SIGNALING AND CANCER 
Protein Kinase A isozymes: Features of 
regulatory and catalytic subunits  
A major function of cAMP in eukaryotes 
is the activation of PKA. cAMP acts in 
mammalian cells by binding to two distinct 
isoforms of PKA, defined PKA-I and PKA-
II. PKA-I and PKA-II differ in regulatory 
(R) subunits, termed RI in PKA-I and RII in 
PKA-II, respectively. PKA holoenzymes are 
inactive heterotetramers. Binding of two 
cAMP molecules to each of the regulatory 
subunits results in the release and activation 
of the catalytic subunits. These catalytic 
subunits will phosphorylate serine and thre-
onine residues on specific substrate proteins 
both in the cytoplasm and in the nucleus 
(Skalhegg and Tasken, 2000).  
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The major nuclear targets of PKA are the 
transcription factors of the cAMP response 
element binding (CREB) family (Mayr and 
Montminy, 2001). CREB proteins bind op-
timally to palindromic CREs (sequence 
TGACGTCA) in promoters and upon phos-
phorylation by PKA they recruit the coacti-
vator, CREB binding protein (CBP) to the 
promoter. Such a phosphorylation event re-
sults in the induction of cellular gene expres-
sion (Sands and Palmer, 2008). The im-
portance of CREB for several physiological 
events has been confirmed by the high num-
ber of targets identified so far: up to 4000 
genes involved in several cellular processes. 
Moreover, several lines of evidence obtained 
from studies on leukemia, fusion oncopro-
teins, viral oncoproteins and endocrine tu-
mors support the notion that CREB is in-
volved in oncogenesis (Siu and Jin, 2007; 
Sakamoto and Frank, 2009). 
The regulatory subunits are highly dy-
namic multi-domain proteins that interact 
with a variety of proteins in addition to serv-
ing as major receptors for cAMP (Kim et al., 
2007; Wu et al., 2007). Although there are 
multiple isoforms (Iα and Iβ, IIα and IIβ), all 
retain the same general architectural organi-
zation. All have a dimerization/docking 
(D/D) domain at the N-terminus, which is 
the docking site for the A kinase-anchoring 
proteins, AKAPs (Gold et al., 2006). The 
D/D domain is followed by an inhibitor site 
(a pseudosubstrate for RI subunits and a sub-
strate site for RII subunits) and two cAMP 
binding domains (CBDs), referred to here as 
domains A and B. Structures of the cAMP 
bound conformations of RIα and RIIβ re-
vealed that the CBDs were conserved motifs 
that resemble the catabolite gene activator 
protein (CAP) in bacteria (Su et al., 1995; 
Diller et al., 2001; Kim et al., 2005). Differ-
ent subunit isoforms (RIα, RIβ, RIIα, and 
RIIβ) have different affinities for cAMP, 
thus originating holoenzymes (PKA type I or 
PKA type II with different subunit composi-
tion and affinity for cAMP and thus are acti-
vated at either low or high local concentra-
tions of cAMP in the cell (Skalhegg and 
Tasken, 2000). Typically PKA type I holo-
enzyme have higher affinity for cAMP than 
type II holoenzyme. When RI subunits are 
up-regulated, cAMP sensitivity of PKA in-
creases and thereby lowers the threshold for 
activation of cAMP-mediated downstream 
effects. Furthermore, only PKA-II but not 
PKA-I undergoes autophosphorylation 
(Rosen and Erlichman, 1975), which serves 
as a “feed-forward” signal by enhancing the 
cAMP responsiveness of PKA-II (Martin et 
al., 2007). 
The four types of regulatory subunits 
have different expression patterns in mam-
mals (Skalhegg and Tasken, 2000). More-
over, during both physiological and patho-
logical conditions, the composition of the 
PKA holoenzyme as well as their intracellu-
lar localization may change, inducing differ-
ent effects. While RIα has ubiquitous distri-
bution, RIβ is expressed primarily in brain, 
testis and B- and T-lymphocytes. Similarly, 
RIIα has ubiquitous distribution, while RIIβ 
is expressed in brain, adipose, and some en-
docrine tissues. Besides cAMP affinity, lo-
calization of the holoenzyme is also differ-
ent, with PKA type I enzymes being general-
ly cytoplasmic, and type II enzymes specifi-
cally anchored to subcellular structures and 
compartments. The AKAPs play an im-
portant role in differential targeting of PKA 
types I and II in the cell. The RIα and RIβ 
subunits are dissimilar, but reveal high ho-
mology (81 % identity at the amino acid lev-
el) as do the RIIα and RIIβ subunits (68 % 
identity at the amino acid level). Importantly, 
as reported below in “PKA signaling and 
cancer” section, PKA type I is associated 
with growth and proliferation whereas PKA 
type II is associated with  increased differen-
tiation and decreased proliferation. In mam-
malian cells there are three isoforms of the 
C-subunit and the two major isoforms (Cα 
and Cβ) have multiple splice variants that 
introduce diversity into the first exon 
(Skalhegg and Tasken, 2000). This isoform 
diversity is an important mechanism for 
achieving specificity in PKA signaling. All 
the C subunits (Cα, Cβ, Cγ) have catalytic 
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core motifs that are common to all protein 
kinases. The catalytic subunit is a nearly 
globular protein, of approximately 250 ami-
no acids, with two lobes: a small and highly 
dynamic amino-terminal lobe (N-lobe) that 
is mostly beta strands, involved in MgATP-
binding, and a larger mostly helical carboxy-
terminal lobe (C-lobe) that contains much of 
the catalytic machinery as well as the major 
substrate docking sites. Both MgATP and 
the peptide come together for catalysis in the 
cleft between the two lobes. In addition to 
the core, the C-subunit of PKA is flanked by 
an N-terminal tail (N-tail) and a C-terminal 
tail (C-tail). These tails are an integral part of 
the C-subunit. Both are anchored to the N- 
and C-lobes of the core and thus can be 
thought of as cis-regulatory elements (Kim et 
al., 2007; Wu et al., 2007). The C-tail (resi-
dues 301–350), in particular, is an integral 
part of the active enzyme. The crystal struc-
ture of the murine Cα subunit was the first 
protein kinase crystal structure available and 
has served as a template for modeling of all 
the other kinases (Knighton et al., 1991a). 
 
PKA signaling and cancer 
Several converging data reveal that the 
cAMP/PKA signaling pathway is altered in 
different cancers and may be exploited for 
cancer therapy and/or diagnosis (Naviglio et 
al., 2009a). 
Cell cycle regulation is a key event in 
cancer development. Multiple intracellular 
signaling pathways modulate various events 
during cell cycle progression. cAMP and 
PKA play different roles in this process 
(Stork and Schmitt, 2002). Low cAMP levels 
are detected at mitosis, while higher levels 
are present in G1 and early S; on the other 
hand, PKA phosphorylates macromolecular 
complexes responsible for the destruction of 
mitotic cyclins and separation of the sister 
chromatids at anaphase-metaphase transition 
(Ferrari, 2006). PKA may act synergistically 
with Epac to induce mitogenesis in endo-
crine cells (Hochbaum et al., 2008). 
By modulating the timing and localiza-
tion of cAMP production, it is possible to 
affect the activation of PKA (and also of 
other cAMP effectors), that in turn can act 
on the RAS/ERK and/or other signaling 
pathways, involved in cell cycle progression 
(Waschek et al., 2006; Stork and Schmitt, 
2002). 
The cAMP/PKA pathway has been re-
ported to stimulate cell growth in many cell 
types while inhibiting it in others (Stork and 
Schmitt, 2002; Insel et al., 2012). An in-
volvement of PKA in neoplastic transfor-
mation and tumor growth, especially in the 
onset and maintenance of endocrine tumors 
(hormone-responsive tissues), mainly of the 
corticotroph axis (pituitary and adrenal cor-
tex) and the thyroid, is clearly indicated (Ri-
vas and Santisteban, 2003; Mantovani et al., 
2008a). 
Moreover, the RIα expression, both at 
protein and mRNA level, has been found to 
be up-regulated in a series of transformed 
cell lines and human tumors (Bradbury et al., 
1994; McDaid et al., 1999; Miller, 2002; 
Mantovani et al., 2008b; Loilome et al., 
2011). Indeed several studies have indicated 
that inhibition of RIα expression through an-
tisense oligonucleotides resulted in growth 
arrest of several tumor cell lines (Cho-
Chung, 2004). On the other hand, overex-
pression of RIIβ inhibits cancer cell growth 
and induces a reverted phenotype in various 
cancer cell lines (Nesterova et al., 1996), in-
cluding prostate carcinoma cells.  In prostate 
tumors, the cAMP pathway may also interact 
with the androgen receptor, by enhancing its 
activation (Merkle and Hoffmann, 2011). 
Thus, uncontrolled proliferation and ma-
lignant transformation have been associated 
mainly with an increase of RI expression or 
changes in the ratio of PKA-I and –II (Bossis 
and Stratakis, 2004). Accordingly, the syn-
thesis of RI and RII subunits and the relative 
abundance of PKA-I and PKA-II isoforms 
are differentially regulated during differenti-
ation, cell growth, and neoplastic transfor-
mation, with expression of PKA-II predomi-
nantly found in normal non-proliferating tis-
sues and in growth-arrested cells, whereas 
enhanced levels of PKA-I are detected stead-
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ily in tumor cells and transiently in normal 
cells exposed to mitogenic stimuli (Neary et 
al., 2004). In addition, PKA-I and its regula-
tory subunit RIα are induced following trans-
formation by certain oncogenes, such as ras 
(Neary et al., 2004).  
On the other hand, RIα-inactivating mu-
tations (germline or somatic mutations) re-
sult in a higher PKA activity by enzymatic 
studies, are associated with altered PKA 
subunits expression and aberrant PKA sig-
naling, and have been found to cause prima-
ry pigmented nodular adrenocortical disease, 
the Carney complex, a multiple neoplasia 
syndrome, and sporadic endocrine tumors 
(Kirschner et al., 2000; Bossis et al., 2004; 
Bourdeau et al., 2006). Moreover, RIα null 
mouse embryonic fibroblasts (MEFs), show-
ing a constitutive PKA activation, became 
immortalized in correlation with up-
regulation of D-type cyclins (Nadella and 
Kirschner, 2005) and showed a decreased 
autophagy, a mechanism that can be associ-
ated with transformation inhibition (Mav-
rakis et al., 2006; Sharma et al., 2014). 
Overall, overexpression of PKA-I iso-
form, as compared with the PKA-II one, is 
considered a hallmark of most human tu-
mors, correlating with more serious clinico-
pathological features in several tumor types 
(Cho-Chung and Nesterova, 2005; Tortora 
and Ciardiello, 2002). Furthermore, PKA 
catalytic β subunit has been shown to be a 
direct transcriptional target of c-MYC, and 
proposed as a crucial component of the pro-
gram by which constitutive c-MYC expres-
sion contributes to cell transformation (Wu 
et al., 2002). 
The PKA pathway has become of great 
interest to the study of aging, since mutations 
that cause a reduction in PKA signaling have 
been shown to extend lifespan in yeast, and 
to both delay the incidence and severity of 
age-related disease, and to promote leanness 
and longevity in mice. There is increasing 
interest in the potential for the inhibition or 
redistribution of adiposity to attenuate aging 
and obesity-related diseases, including can-
cer, since obesity is associated with impaired 
function of most organ systems, and is a 
strong risk factor for both shortened life span 
and tumors. Therefore, gene signaling path-
ways such as PKA, that play a key role in the 
regulation of metabolism and triglyceride 
storage, are potential inhibitory targets for 
obesity and aging intervention (Enns and 
Ladiges, 2010). 
At this regard, it has been found that 
PKA catalytic β subunit is involved in diet-
induced obesity, since Cβ subunit null ani-
mals appear overtly normal when fed stand-
ard rodent chow, whereas they are protected 
from diet-induced obesity, steatosis, dyslipo-
proteinemia and insulin resistance, without 
any differences in caloric intake or locomo-
tor activity (Enns et al., 2009).  
Notably, given the relevant role of obesi-
ty-linked cytokine leptin in breast cancer 
growth and metastasis, the leptin system has 
emerged as a new and promising therapeutic 
target for breast cancer and strategies to 
counteract biological effects of this obesity-
linked cytokine are warranted (Gertler and 
Solomon, 2013). Interestingly, our previous 
studies provided initial evidence for the effi-
cacy of cAMP elevation against the onco-
genic effects of leptin in triple negative 
breast cancer cells, via PKA modulation 
(Spina et al., 2013).  
Recently, we demonstrated that in MDA-
MB-231 breast cancer cells, intracellular 
cAMP elevation completely abrogates both 
ERK1/2 and STAT3 phosphorylation in re-
sponse to leptin, strongly lowers protein lev-
els of both regulatory RIα and catalytic sub-
units of PKA, with a consistent reduction of 
CREB phosphorylation, and inhibits both 
leptin-induced proliferation and migration. 
(Naviglio et al., 2009b; Naviglio et al., 2010; 
Spina et al., 2012). 
Another function, in which PKA may 
operate and may be dysregulated in cancer, 
is the actin-based cell migration, that in-
volves cytoskeleton remodeling. PKA regu-
lates actin dynamics, by targeting structural 
proteins, like actin, integrins, VASP and 
myosin light chain, and regulatory proteins, 
like Rho GTPases, Src kinases, p21-
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activated kinases, phosphatases and proteas-
es (Howe, 2004). The involvement of PKA 
in migration of breast carcinoma cells has 
been descαbed (Jiang et al., 2009) and also in 
ovarian cancer cell migration and invasion 
(McKenzie et al., 2011) . 
Recently, it has also been shown that hy-
poxia enhances PKA activity by up-
regulating PKA gene expression in a HIF 
dependent mechanism and that PKA plays a 
key role in hypoxia-mediated EMT, migra-
tion, and invasion in lung cancer cells 
(Shaikh et al., 2012). 
Furthermore, PKA has been clearly 
shown to be involved in drug resistance in 
human cancer cells (Gausdal et al., 2013; de 
Leeuw et al., 2013). 
Additionally, recent clinical studies, ei-
ther measuring autoantibodies for PKA 
(Nesterova et al., 2006) or its enzymatic ac-
tivity (Wang et al., 2007) in serum patients, 
strongly suggest that PKA may function as a 
cancer marker for various human cancers 
and can be used in cancer detection and for 
monitoring response to therapy. 
Overall, based on the above considera-
tions, PKA selective targeting in antitumour 
strategies has become very attractive and 
will be discussed below.  
 
TARGETING PKA IN  
CANCER THERAPY 
Site-selective cAMP analogs and antisense 
strategy 
The interest in cyclic nucleotides as the-
rapeutics against cancer started in the late 
1980s, when Cho-Chung and colleagues dis-
covered that 8-Cl-cAMP, a potent site-
selective analog of cAMP, induced growth 
inhibition in vitro and in vivo in a broad 
spectrum of human carcinomas (breast, co-
lon, lung), fibrosarcomas, and leukemias at 
micromolar concentrations, and in animal 
models.  Since then other cAMP analogs 
have been developed, but further studies 
have been mainly conducted with 8-Cl-
cAMP, most readily available by synthesis 
and promising enough to be tested as a drug 
(Schwede et al., 2000).  
8-Cl-cAMP can discriminate between the 
two cAMP binding sites (sites A and B) on 
the R-subunits (RI and RII) of PKA-I 
and -II. 8-Cl-cAMP binds with similar high 
affinity to both sites A and B of RI. In con-
trast, it binds with high affinity to site B of 
RII, but with low affinity to site A, which 
may keep this isozyme in its nonactivated 
holoenzyme form (Schwede et al., 2000). As 
above focused, overexpression of PKA-I iso-
form occurs in most human tumors and has 
been associated with cell transformation and 
proliferation while growth arrest and differ-
entiation have been linked to a decreased ra-
tio of RI/RII. 8-Cl-cAMP was found to mod-
ulate RI and RII levels, leading to the resto-
ration of a more natural RI/RII balance in 
cancer cells (Rohlff et al., 1993; Noguchi et 
al., 1998). 8-Cl-cAMP is able to down-
regulate RIα, perhaps by facilitating the deg-
radation of the protein after its dissociation 
from the PKA holoenzyme, while RIIβ ex-
pression is up-regulated at the transcriptional 
level or not affected, both leading to an in-
creased RII/RI intracellular ratio. In preclini-
cal studies, 8-Cl-cAMP was shown to inhibit 
the expression of c-myc and c-ras, to revert 
the transformed phenotype, and to cause in-
hibition of cancer cell growth through both 
anti-proliferation and pro-apoptotic mecha-
nisms (Cho-Chung and Nesterova, 2005). 
Yet, despite the well-documented effects 
of 8-Cl-cAMP and the above pioneering 
studies by the group of Yoon Cho-Chung, 
actually there is no common agreement on 
its mechanism of action, and the results of 
more recent studies suggest that the effects 
of 8-Cl-cAMP might be also mediated by its 
metabolite 8-Cl-adenosine and might be in-
dependent of PKA activation and/or altera-
tions of the ratio between type I and type II 
R subunits (Robinson-White et al., 2008; 
Lucchi et al., 2011; Choi et al., 2013). 
However, although the mechanism of ac-
tion of 8-Cl-cAMP is debated and it is still 
not completely clear whether 8-Cl-cAMP 
acts as a pharmacon itself or, at least in part, 
as a prodrug for 8-Cl-adenosine via a PKA-
independent manner, recently, it has been 
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evaluated in phase I/II clinical trials as an 
anticancer agent (Propper et al., 1999; Tor-
tora and Ciardiello, 2002). 
Clear evidence that RI subunit of PKA 
was a positive effector of cancer cell growth 
was provided by antisense strategy data 
(Cho-Chung, 2004). A synthetic RI antisense 
oligodeoxynucleotide (ODN) corresponding 
to the N-terminus (the first 21 bases) of the 
human RIα produced growth inhibition in 
human cancer cells of epithelial origin, in-
cluding breast (MCF-7), colon (LS-174T), 
and gastric (TMK-1) carcinoma and neuro-
blastoma (SK-N-SH) cells, as well as HL-60 
leukemia cells  with no sign of cytotoxicity. 
Moreover, treatment with RIα antisense 
phosphorothioate oligodeoxynucleotide (PS-
ODN) brought about a marked reduction in 
RIα protein levels accompanied by an in-
crease in RIIß protein levels due to an in-
crease in  RIIß protein half-life. This com-
pensatory stabilization of RII protein repre-
sents an important biochemical mechanism 
of RI antisense that ensures both a depletion 
of growth-promoting RI subunit and an in-
crease of RII, the growth-inhibitory and dif-
ferentiation-inducing protein, leading to sus-
tained inhibition of tumor cell growth 
(Nesterova et al., 2000). Importantly, a sin-
gle subcutaneous injection of RIα antisense 
PS-ODN to 8-13 codons of human RI into 
nude mice bearing LS-174T human colon 
carcinoma resulted both in a reduced RIα 
expression and an almost complete suppres-
sion of tumor growth for up to 14 days of 
examination without apparent sign of sys-
temic toxicity, whereas tumors in untreated, 
saline-treated, or control antisense-treated 
animals showed continued growth 
(Nesterova and Cho-Chung, 1995). Further-
more, a second-generation RNA-DNA 
mixed-backbone (MBO) RIα antisense ODN 
containing both phosphorothioate-modified 
nucleosides and ribonucleosides, more stable 
and resistant to nucleases, has been shown to 
cause growth arrest and differentiation in a 
variety of cancer cell lines in vitro and to ex-
hibit antitumor effects in animal models of 
breast, colon, prostate and lung cancer (Cho-
Chung et al., 1999; Hensley et al., 2011). 
The RNA-DNA mixed-backbone (MBO) 
RIα antisense has demonstrated increased 
biologic activity, minimal polyanionic or 
immunostimulatory side effects, improved in 
vivo stability, and, remarkably, synergizing 
effects with several class of cytotoxic drugs, 
oral efficacy. (Wang et al., 1999, 2002). 
Notably, the MBO AS-PKA-I (defined 
GEM 231) has recently been used for clini-
cal studies (Mani et al., 2003; Goel et al., 
2003, 2006; Tortora and Ciardiello, 2003). 
 
Novel perspectives by new targeted agents 
As the second largest group after G-
protein-coupled receptors, there are more 
than 500 protein kinases. Because of their 
critical effects on cell function, their activity 
is tightly regulated, and thus abnormal phos-
phorylation is linked to various diseases, in-
cluding cancer. 
Accordingly, protein kinases have be-
come very attractive drug targets (Arencibia 
et al., 2013). Thus, designing novel kinase 
specific inhibitors is a major international 
effort. 
To date, a majority of protein kinase in-
hibitors with clinical applications have de-
veloped toward the ATP-binding site (Han et 
al., 2012). 
Although many ATP-competitive small 
molecule inhibitors have demonstrated their 
potency, they have a limitation in their selec-
tivity because of the highly conserved region 
of the ATP-binding site and also because 
these inhibitors have to compete with high 
concentration of intracellular ATP.  
On the other hand, substrate recognition 
by protein kinases exhibits remarkable speci-
ficity, despite their structural and sequence 
homologies in the catalytic domains (Pinna 
and Ruzzene, 1996). 
Because the substrate-binding domain is 
much more diverse than the ATP-binding 
site, substrate-competitive inhibitors are ex-
pected to show higher selectivity (Han et al., 
2012). 
Heat-stable protein kinase A inhibitor 
(PKI) purified and characterized in the early 
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1970s became the first head in the develop-
ment of peptide inhibitors of protein kinases. 
PKI interacts specifically with the catalytic 
domain of PKA, thereby inhibiting kinase 
activity with a Ki of 0.2 nM in the presence 
of ATP (Cheng et al., 1986). 
PKI (5-24) is a potent, competitive, syn-
thetic peptide inhibitor of PKA derived from 
the active domain of the naturally-occurring 
heat-stable inhibitor protein PKI. This pseu-
dosubstrate inhibitor peptide mimics the pro-
tein substrate by binding to the catalytic site 
via the arginine-cluster basic subsite, which 
provides high specificity. PKA catalytic sub-
unit residues Tyr235 and Phe239 form a 
sandwich-like structure with residue Phe10 
of PKI (5-24); this is a prominent enzyme-
substrate interaction site (Knighton et al., 
1991b).  
Despite their selectivity, clinical applica-
tions of such substrate-competitive inhibitors 
are frequently hampered by several obstacles 
including permeability into cells, susceptibil-
ity to proteases and potential immunogenici-
ty. Therefore, more efforts have been di-
rected to the discovery and development of 
substrate competitive inhibitors, particularly 
considering the clinical applicability. 
Generally, the design of substrate-
competitive inhibitors requires comprehen-
sive understanding of structural interaction 
of protein kinases with substrates or regula-
tor proteins.  
PKA was one of the first protein kinases 
to be discovered, the first to be sequenced 
and then cloned and the elucidation of its 
structure provided the first three dimensional 
template for this family (Knighton et al., 
1991a; Madhusudan et al., 2002). Moreover, 
the structures of the regulatory subunits of 
PKA also have been elucidated previously 
(Su et al., 1995; Diller et al., 2001), but it is 
only recently that the structure solution of 
holoenzyme complexes have been resolved 
(Kim et al., 2007; Wu et al., 2007). From 
these structures the kinase has started to be 
considered as a scaffold, in addition to its 
role as a catalyst; in fact every part of its sur-
face seems committed to some type of pro-
tein:protein interaction and these interactions 
appear to be as essential to its function as is 
phosphoryl transfer. The regulatory and cata-
lytic subunits have been considered as sepa-
rate proteins for more than a decade where 
they served as prototypes for the protein ki-
nase superfamily and for cAMP binding do-
mains, respectively. Now, instead, they can 
be considered as part of larger protein com-
plexes and the understanding of how regula-
tory and catalytic subunits contribute to the 
assembly and disassembly of macromolecu-
lar signaling complexes will be made a great 
deal easier by these structures.  
In other words, by solving crystal struc-
tures of holoenzyme complexes of PKA, the 
molecular features required for inhibition 
and for cAMP-induced activation and the 
entire range of strategies for designing inhib-
itors and interfering with PKA signaling can 
be fully appreciated (Taylor et al., 2013).  
Thus, the approach to PKA inhibitor de-
sign could be not aimed exclusively at mole-
cules that target the ATP binding pocket and 
substrate tethering sites for the catalytic sub-
unit, but also inhibitors that target the activa-
tion of the kinase could be designed and are 
presumed very attractive as therapeutic 
agents.  
The regulatory subunits, for instance, un-
dergo major conformational changes as they 
release cAMP and wrap around the catalytic 
subunit. In the process of binding to the cata-
lytic subunit, the cAMP binding sites 
(CBDs) are completely restructured. The 
Phosphate Binding Cassette (PBC) where the 
ribose phosphate docks, for example, is far 
removed from the residues that cap the ade-
nine ring in the holoenzyme complex. This 
provides a new paradigm for designing novel 
agonists or antagonists for PKA (Taylor et 
al., 2013).  
The AKAPs introduce another level of 
complexity into PKA signaling by localizing 
PKA in close proximity to its physiological 
substrates. A strategy aimed at disrupting 
PKA targeting to substrates is predicted to be 
equally effective. The docking motifs are 
also valid targets for designing inhibitors that 
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disrupt targeting. Furthermore, with the 
structure solutions of targeting motifs, novel 
mechanisms for disrupting targeting are also 
being implemented (Tröger et al., 2012).  
Moreover, an additional strategy for tar-
geting PKA activity is to affect cAMP levels 
by manipulating its synthesis and/or degra-
dation, via adenylyl cyclases and/or subtype-
specific phosphodiesterase, respectively (Pa-
van et al., 2009; Maurice et al., 2014).  
 
CONCLUDING REMARKS 
The protein kinases play a key regulatory 
role in cellular signaling pathways and their 
abnormal phosphorylation activity is insepa-
rably linked with various human diseases, 
including cancer.  
Accordingly, protein kinases have be-
come invaluable drug targets and considera-
ble effort has gone into the discovery of pro-
tein kinase inhibitors.  
PKA has also emerged as major thera-
peutic target. PKA targeting is largely 
known to control cell growth in many cancer 
types in vitro and in vivo; remarkably, tar-
geting PKA by either site-selective cAMP 
analogs or antisense approaches has clearly 
shown antitumor activity in cancer patients. 
However, discovering further PKA inhibitors 
is desirable.  
Although strategies including bioinfor-
matics, computational modeling, and high-
throughput screening are often employed for 
designing specific kinase inhibitors, an in-
valuable guidance in developing inhibitors 
and interfering with PKA signaling will cer-
tainly rise from the structure solution of 
PKA holoenzyme complexes. 
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